Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Adenylate cyclase 10/ADCY10 CRISPR Activation Plasmid (m): sc-435448-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Adenylate cyclase 10/ADCY10 CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Adenylate cyclase 10/ADCY10 CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Adenylate cyclase 10/ADCY10 CRISPR Activation Plasmid (m) and Adenylate cyclase 10/ADCY10 CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Adcy10 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Adenylate cyclase 10/ADCY10 Antibody (B-1): sc-515097
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Adenylate cyclase 10/ADCY10 CRISPR Activation Plasmid (m) | sc-435448-ACT | 20 µg | $397.00 | |||
Adenylate cyclase 10/ADCY10 CRISPR Activation Plasmid (m2) | sc-435448-ACT-2 | 20 µg | $397.00 |
Adcy10 encodes adenylate cyclase 10 (ADCY10), an atypical, bicarbonate- and Ca2+-regulated “soluble” adenylyl cyclase that generates cAMP independently of G protein–coupled receptor signaling. By controlling local cAMP production, ADCY10 modulates PKA- and EPAC-dependent signaling, influencing phosphorylation networks, ion transport, and transcriptional programs such as cAMP response element (CRE)-mediated gene regulation. In mouse systems, Adcy10 activity is frequently studied in the context of intracellular pH/CO2 sensing, metabolic and mitochondrial cAMP microdomains, and signaling cross-talk with calcium dynamics. Dysregulated cAMP signaling is broadly implicated in defects in cellular homeostasis and signaling-dependent phenotypes, supporting use of Adcy10 as a mechanistic node in pathway-focused disease models without implying clinical outcomes.
Adenylate cyclase 10/ADCY10 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Adcy10 expression without altering the underlying DNA sequence.
Adenylate cyclase 10/ADCY10 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Adcy10 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Adcy10 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Adenylate cyclase 10/ADCY10 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Adcy10 locus and enabling the study of Adenylate cyclase 10/ADCY10-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Adenylate cyclase 10/ADCY10 pathway restoration in tumor cells with silenced or reduced Adcy10 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.